In fact, two recent clinical trials (NCT04750577 and NCT04736628) on the novel, potent sGC activator avenciguat have demonstrated that it improves albuminuria in patients with CKD, both with and without type 2 diabetes mellitus (Heerspink et al., 2024). Here, SGCB is linked to type 2 diabetes mellitus.